A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study - Archive ouverte HAL Access content directly
Journal Articles Blood Cancer Journal Year : 2020

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

(1) , (1) , (2) , (2) , (1) , (1) , (1) , (1) , (2) , (2) , (2) , (2) , (3) , (4) , (3) , (2) , (2) , (2) , (2) , (2) , (1)
1
2
3
4

Abstract

Targeted next-generation sequencing (tNGS) and ex vivo drug sensitivity/resistance profiling (DSRP) have laid foundations defining the functional genomic landscape of acute myeloid leukemia (AML) and premises of personalized medicine to guide treatment options for patients with aggressive and/or chemorefractory hematological malignancies. Here, we have assessed the feasibility of a tailored treatment strategy (TTS) guided by systematic parallel ex vivo DSRP and tNGS for patients with relapsed/refractory AML (number NCT02619071). A TTS issued by an institutional personalized committee could be achieved for 47/55 included patients (85%), 5 based on tNGS only, 6 on DSRP only, while 36 could be proposed on the basis of both, yielding more options and a better rationale. The TSS was available in <21 days for 28 patients (58.3%). On average, 3 to 4 potentially active drugs were selected per patient with only five patient samples being resistant to the entire drug panel. Seventeen patients received a TTS-guided treatment, resulting in four complete remissions, one partial remission, and five decreased peripheral blast counts. Our results show that chemogenomic combining tNGS with DSRP to determine a TTS is a promising approach to propose patient-specific treatment options within 21 days.
Fichier principal
Vignette du fichier
Collignon2020.pdf (1.57 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03038330 , version 1 (03-12-2020)

Identifiers

Cite

A. Collignon, M. A Hospital, C. Montersino, F. Courtier, A. Charbonnier, et al.. A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood Cancer Journal, 2020, 10 (6), pp.64. ⟨10.1038/s41408-020-0330-5⟩. ⟨inserm-03038330⟩
76 View
59 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More